OneDigital Investment Advisors LLC Invests $560,000 in Moderna, Inc. $MRNA

OneDigital Investment Advisors LLC acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 7,996 shares of the company’s stock, valued at approximately $560,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System bought a new position in shares of Moderna during the 1st quarter valued at $899,000. Lingotto Investment Management LLP grew its holdings in shares of Moderna by 33.7% in the fourth quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company’s stock worth $14,706,000 after acquiring an additional 125,598 shares during the period. Contravisory Investment Management Inc. increased its position in Moderna by 1,387.6% during the second quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock valued at $1,696,000 after acquiring an additional 22,590 shares during the last quarter. Nicollet Investment Management Inc. purchased a new stake in Moderna during the fourth quarter valued at $897,000. Finally, Capital World Investors purchased a new stake in Moderna during the fourth quarter valued at $378,299,000. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

NASDAQ MRNA opened at $62.96 on Wednesday. The business’s fifty day moving average is $62.34 and its 200 day moving average is $53.94. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $85.60. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The company has a market capitalization of $25.14 billion, a PE ratio of -7.88 and a beta of 0.91.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the prior year, the business posted ($2.13) earnings per share. The business’s quarterly revenue was up 2.1% on a year-over-year basis. Sell-side analysts predict that Moderna, Inc. will post -6.2 earnings per share for the current year.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 9,263 shares of Moderna stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the transaction, the director owned 3,924 shares of the company’s stock, valued at $183,800.16. The trade was a 70.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 66,070 shares of company stock worth $3,347,299. 10.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on MRNA shares. Wolfe Research reissued an “underperform” rating and issued a $25.00 target price on shares of Moderna in a research report on Monday, July 20th. Bank of America upped their price target on shares of Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. The Goldman Sachs Group increased their price objective on shares of Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 21st. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Thursday, June 18th. Finally, UBS Group restated an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Reduce” and a consensus price target of $42.13.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.